Product Name: Human VEGFR2 / KDR / CD309 Antibody (AT001, Research Use)
Catalog Number: NBR-0938
Target Name: VEGFR2 / KDR / CD309
Trade Name: AT001
Antibody Drug Description: AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). AT-001 is currently being studied in a Phase 3 registrational study in DbCM. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: KDR
Synonyms: CD309; FLK1; VEGFR; VEGFR2
Target Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. 
Ensembl: ENSG00000128052
Uniprot: P35968